International Urology and Nephrology最新文献

{"title":"Comparison of cognitive magnetic resonance-ultrasonography fusion prostate biopsy outcomes in left lateral decubitus vs lithotomy positions: a prospective randomized study cognitive magnetic resonance-ultrasonography fusion prostate biopsy.","authors":"Zeki Bayraktar, Emre Burak Sahinler, Salih Yildirim, Nuri Oguzhan Saglam, Sedat Can Birinci, Orhun Sinanoglu, Cahit Sahin","doi":"10.1007/s11255-025-04544-9","DOIUrl":"https://doi.org/10.1007/s11255-025-04544-9","url":null,"abstract":"<p><strong>Introduction: </strong>The study compares the results of cognitive MRI-ultrasonography fusion prostate biopsy in two positions: left lateral decubitus (LLD) and lithotomy.</p><p><strong>Methods: </strong>From June 2023 to December 2024, 200 patients were randomly assigned to two groups (100 in LLD and 100 in lithotomy). Age, BMI, prostate volume, comorbidities, PSA levels, DRE (+) status, and PI-RADS ≥ 3 lesions were recorded. Pain was measured using the visual analog scale (VAS), and complications were monitored. Histopathological results were collected and analyzed.</p><p><strong>Results: </strong>No significant differences were found between the groups in terms of age, BMI, PSA, DRE status, prostate volume, comorbidities, or PI-RADS ≥ 3 lesions. Cancer detection rates were 38% in the LLD group and 32% in the lithotomy group (p = 0.550). The average VAS score was lower in the LLD group (2.41 ± 2.30) compared to the lithotomy group (3.22 ± 2.88) (p = 0.030). The mean Gleason score was similar between groups (LLD: 7.05 ± 1.11, Lithotomy: 7.29 ± 1.04; p = 0.247). No major complications occurred, but hematuria was more frequent in the lithotomy group (p = 0.006).</p><p><strong>Conclusions: </strong>There were no significant differences in cancer detection rates or grades between the two groups. The lithotomy position had slightly higher pain scores but no major complications. Hematuria occurred more often in the lithotomy position. Cognitive MRI-US fusion biopsy is safe in both positions.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early post-treatment remission of proteinuria is associated with long-term prognosis in patients with immunoglobulin A nephropathy.","authors":"Xinyi Fang, Xianjin Bi, Tangli Xiao, Liangyu Yin, Jun Zhang, Liangjing Lv, Jiachuan Xiong, Jinghong Zhao","doi":"10.1007/s11255-025-04548-5","DOIUrl":"https://doi.org/10.1007/s11255-025-04548-5","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the relationship between remission status and the optimal thresholds of proteinuria and hematuria after 6 months of treatment in patients with Immunoglobulin A Nephropathy (IgAN), and to assess their predictive value for long-term prognosis.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 440 IgAN patients. Receiver Operating Characteristic (ROC) curves were employed to determine the optimal thresholds for proteinuria and hematuria remission at 6 months post-treatment initiation. Patients were stratified into four groups based on these thresholds and their remission status. Comparative analysis of baseline clinical characteristics was performed across groups. Kaplan-Meier survival analysis was utilized to assess differences in composite kidney outcomes, and multivariate Cox regression analyses were conducted to evaluate the relationship between remission patterns and these outcomes.</p><p><strong>Results: </strong>The optimal thresholds for remission were identified as 0.80g/g for urinary protein and 13 RBC/μl for hematuria. Significant disparities in systolic blood pressure, diastolic blood pressure, body mass index, hemoglobin, serum creatinine, and estimated Glomerular Filtration Rate (eGFR) were observed among the four groups. During a median follow-up period of 33 months, 67 composite kidney events were recorded. Kaplan-Meier analysis revealed that patients achieving remission in both proteinuria and hematuria exhibited the highest survival rates, contrasting with the lowest rates in those with persistent proteinuria and hematuria (P < 0.001). Log-rank test analysis revealed no statistically significant differences in survival rates between the complete remission and proteinuria remission with persistent hematuria groups (P = 0.099), nor between the proteinuria persistence with hematuria remission and complete persistence groups (P = 0.513). Multivariate Cox analysis revealed that arteriolar hyalinosis is an independent risk factor for composite renal endpoint events in IgAN patients (HR, 2.687; 95%CI, 1.158-6.235; P = 0.021). Compared to the complete remission group, both the proteinuria persistence with hematuria remission group (HR, 8.649; 95%CI, 2.353-31.792; P = 0.001) and the complete persistence group (HR, 6.580; 95%CI, 1.936-22.360; P = 0.003) exhibited significantly higher risks of reaching endpoint events. Elevated baseline hemoglobin levels can reduce the risk of disease progression in IgAN patients (HR, 0.982; 95%CI, 0.967-0.996; P = 0.013).</p><p><strong>Conclusion: </strong>Proteinuria remission is significantly associated with long-term prognosis in IgAN patients. Achieving proteinuria levels below 0.80 g/g after 6 months of initial treatment may indicate favorable control targets in IgAN management.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for coronary artery calcification in Chinese patients undergoing maintenance hemodialysis: a meta-analysis.","authors":"Mengjiao Li, Yuxia Li, Shuting Liu, Yan Yang, Ping Jiang","doi":"10.1007/s11255-025-04535-w","DOIUrl":"https://doi.org/10.1007/s11255-025-04535-w","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Chronic kidney disease (CKD) progression to end-stage renal disease (ESRD) increases cardiovascular disease (CVD) risk, with coronary artery calcification (CAC) affecting 70% of Chinese maintenance hemodialysis (MHD) patients. Prolonged MHD treatment is linked to calcium-phosphorus imbalance and accelerated CAC progression. However, conflicting findings on CAC risk factors persist due to methodological heterogeneity in existing studies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To systematically analyze the risk factors for coronary artery calcification in patients undergoing maintenance hemodialysis in China.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We conducted a computer-assisted search of ten databases, including PubMed, Web of Science, CBM, Wanfang, CNKI, and VIP, for observational studies (cohort, case-control, and cross-sectional studies) published from inception to October 21, 2024, on risk factors for coronary artery calcification (CAC) in Chinese patients with maintenance hemodialysis (MHD). The studies were independently screened by two investigators according to the PRISMA guidelines and diagnosed with coronary artery calcification through imaging techniques (CT). Odds ratios (ORs) and 95% confidence intervals (CIs) were used for the reported outcomes. The quality of the studies was assessed using the Newcastle-Ottawa Scale. A meta-analysis of the included data was performed using either a random effects model or a fixed effects model, we performed a meta-analysis using the Stata 17.0 software.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The review included 24 studies with a total sample size of 2,875 patients. A meta-analysis of these 24 studies (n = 2875) found that diabetes mellitus (OR = 2.32, 95% CI 1.37-3.27) and elevated iPTH (OR = 1.59, 95% CI 1.21-1.96) were the strongest predictors of an increased risk of coronary artery calcification (CAC) in Chinese maintenance hemodialysis (MHD) patients. Additionally, elevated high-sensitivity C-reactive protein (hs-CRP) levels, elevated serum calcium, advanced age, longer duration of dialysis treatment, elevated serum phosphorus, and elevated sclerostin (SOST) levels were significant predictors of an increased risk of concurrent CAC in Chinese MHD patients. However, the correlation between hypertension, serum magnesium, fibroblast growth factor-23 (FGF-23), alkaline phosphatase (ALP), and MHD with concomitant CAC was not significant, likely due to the wide variation in sample size and study type.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Diabetes mellitus and elevated iPTH are the most significant clinical risk factors for coronary artery calcification (CAC) in Chinese maintenance hemodialysis (MHD) patients, and healthcare professionals should prioritize this population. Additionally, monitoring calcium and phosphorus metabolism, along with inflammatory markers (e.g., hs-CRP, SOST), can further reduce the risk of cardiovascular disease. Early health education and targeted, individualized t","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DNMT1 promotes bladder cancer progression and immune escape by inhibiting MYH11 expression by methylating its promoter.","authors":"Shan Gao, Tianyi Liu, Qing Liu","doi":"10.1007/s11255-025-04527-w","DOIUrl":"https://doi.org/10.1007/s11255-025-04527-w","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer (BC) is a fatal malignancy of the urinary tract with limited effective biomarkers and therapeutic targets. This paper delved into the mechanism of MYH11 and DNMT1 in BC progression.</p><p><strong>Methods: </strong>Differential genes obtained from the GSE3167 dataset were analyzed by the R language limma package. RT-qPCR, Western blot, and immunohistochemistry were carried out to assess MYH11 and DNMT1 expression in BC cell lines and BC tissues. Cell migration, invasion, proliferation, and apoptosis were detected by Transwell assay, CCK-8, and TUNEL after different lentiviral vector treatments. MB49 cells with different infections were administered into mice to monitor tumor growth and immune escape. Flow cytometry detected the rate of CD45⁺CD4⁺-positive cells in the tumor tissues and PD-1 and TIM-3 expression in CD4⁺ T cells. MYH11 methylation was analyzed using the qMSP assay. ChIP and dual-luciferase assay were used for regulatory assays.</p><p><strong>Results: </strong>MYH11 was lowly expressed in BC. Overexpression of MYH11 inhibited the malignant progression of BC cells, promoted anti-tumor immune responses of CD4⁺ T cells, and inhibited immune escape and tumor development in mice. DNMT1 inhibited MYH11 expression by elevating MYH11 promoter methylation. DNMT1 inhibition impeded the immune escape of BC cells, which was reversed by silencing MYH11. DNMT1 silencing prevented immune escape via transcriptional activation of MYH11 and hindered tumor growth in mice.</p><p><strong>Conclusion: </strong>DNMT1 promotes immune escape and malignant progression of BC by methylating the promoter of MYH11.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing patient satisfaction with hemodialysis and peritoneal dialysis care and associated factors in Iran.","authors":"Nastaran Nemati, Mahmood Yousefi, Fatemeh Keshvari-Shad, Soleiman Akbari, Eshagh Barfar","doi":"10.1007/s11255-024-04346-5","DOIUrl":"10.1007/s11255-024-04346-5","url":null,"abstract":"<p><strong>Purpose: </strong>With the increasing demand for dialysis, there is a growing emphasis on patient-centered care. This study investigated patients' satisfaction levels with peritoneal dialysis (PD) and hemodialysis (HD) care in Iran.</p><p><strong>Methods: </strong>A cross-sectional multicenter study was conducted among 346 patients with chronic kidney disease (CKD) covered by the Iran Health Insurance Organization who received dialysis services from October to December 2022 across the country. Data were gathered using a self-made questionnaire through telephone interviews. Data analysis included descriptive statistics, t tests, ANOVA, and linear logistic regression using R software.</p><p><strong>Results: </strong>Patients reported high satisfaction with doctors and nurses, health care facilities, and costs. PD patients had higher overall satisfaction (P < 0.001) and were more satisfied with costs (P < 0.001), while HD patients reported greater satisfaction with doctor and nurse behavior (P = 0.012). Significant factors associated with satisfaction included marital status (P = 0.012), insurance coverage duration (P = 0.027), dialysis type (P < 0.001), and time to dialysis initiation (P = 0.027). Doctor and nurse behavior had the greatest impact on satisfaction (P < 0.001).</p><p><strong>Conclusion: </strong>While patients were generally satisfied with the care provided, the findings revealed areas for improvement, particularly regarding the availability of medical centers and costs among dialysis patients. Focusing on patient education, communication, and supportive insurance policies has the potential to significantly enhance patient satisfaction and improve quality of life for dialysis patients.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"1633-1638"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological features and treatment outcomes of urothelial carcinoma variant histologies and non-urothelial bladder cancers.","authors":"İsmet Seven, Selin Aktürk Esen, Serhat Sekmek, İrfan Karahan, Müge Büyükaksoy, Tuba Dilay Kökenek Ünal, Doğan Uncu","doi":"10.1007/s11255-024-04341-w","DOIUrl":"10.1007/s11255-024-04341-w","url":null,"abstract":"<p><strong>Purpose: </strong>Most bladder cancers are pure urothelial carcinomas, but a small portion, approximately 5-10%, have variant histology or are non-urothelial in nature. This research sought to examine the features of and treatment strategies for different types of urothelial carcinoma with variant histologies and non-urothelial bladder cancer.</p><p><strong>Methods: </strong>The study cohort comprised individuals with non-urothelial and variant urothelial bladder cancers treated at two medical centres in Ankara, Turkey, between 2005 and 2024.</p><p><strong>Results: </strong>A total of 104 individuals were reviewed, with 88 having urothelial cancer with variant histology and 16 having non-urothelial cancer. Non-urothelial cancers included neuroendocrine, undifferentiated, adenocarcinoma, squamous, sarcoma, and carcinosarcoma, with a median overall survival (OS) of 8 months. The most frequent urothelial carcinoma variants were squamous (43 cases), plasmacytoid (9 cases), and sarcomatoid (6 cases). Individuals with operable variants of urothelial malignancies had a median disease-free survival (DFS) of 16.5 months, while individuals with inoperable/metastatic variants experienced a median progression-free survival (PFS) of 8.9 months. The median OS in the operable cohort was 18.5 months, compared to 10.8 months in the inoperable/metastatic group.</p><p><strong>Conclusion: </strong>The present study reveals that variant urothelial and non-urothelial bladder cancers are aggressive in nature and have poor prognosis. Given the significant heterogeneity observed in OS, DFS, and PFS among these rare and diverse tumor subtypes, large-scale multicenter investigations are required to establish a consensus on patient handling and treatment.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"1451-1463"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of soy protein and soy isoflavones intake on chronic kidney disease: a systematic review and meta-analysis.","authors":"Yu Zhixiang, Xu Yongxing, Liu Juan, Yang Qing, Lu Yangyang, Zhen Zhangrui, Gao Yuehua","doi":"10.1007/s11255-024-04301-4","DOIUrl":"10.1007/s11255-024-04301-4","url":null,"abstract":"<p><strong>Purpose: </strong>Existing literatures on the potential impact of soy protein consumption on kidney function present conflicting findings. In this study, a meta-analysis has been conducted to assess the impact of soy protein consumption in comparison to animal protein consumption among individuals with chronic kidney disease (CKD).</p><p><strong>Methods: </strong>A structured electronic search was conducted on Medline, EMBASE, and Cochrane Library for randomized controlled trials published up to March 2024. The outcome measures were serum creatinine (SCR), triglyceride (TG), total cholesterol (TC), calcium (Ca), C-reactive protein, proteinuria, high-density lipoprotein (HDL), low-density lipoprotein (LDL), uric acid (UA) and phosphorus concentrations. Mean differences were calculated for net changes using random-effects models.</p><p><strong>Results: </strong>Eighteen trials with a total of 522 participants were included in this systematic review. The results showed that consumption of soy protein led to a significant decrease in total cholesterol, LDL, and proteinuria levels. The average reduction was  - 20.55 mg/dL (95% CI  - 38.25,  - 2.85 mg/dL) for total cholesterol (P = 0.02),  - 8.26 mg/dL (95% CI  - 13.35,  - 3.17 mg/dL; P = 0.001) for LDL and  - 140.53 (95% CI  - 205.83,  - 75.23 mg/day) for proteinuria. No statistically significant impact was observed on serum creatinine, triglycerides, calcium, C-reactive protein, HDL, uric acid, or phosphorus levels.</p><p><strong>Conclusion: </strong>The findings of the meta-analysis showed a potential protective impact of soy protein intake on hyperlipidemia and proteinuria in CKD patients. It is important to note that the evidence presented may be of limited accuracy due to relatively small number of trials and participants.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"1533-1553"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between the presence of kidney stones and the risk of developing osteoporosis: a NHANES-based cross-sectional study and Mendelian randomization analysis.","authors":"Juefei Dong, Weibin Hou, Guangming Yin, Jinrong Wang, Long Wang, Jianye Liu, Xianzhen Jiang, Jing Tan","doi":"10.1007/s11255-024-04324-x","DOIUrl":"10.1007/s11255-024-04324-x","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate whether the presence of kidney stones increases the risk of developing osteoporosis.</p><p><strong>Methods: </strong>First, we performed an observational study on the basis of data from the National Health and Nutrition Examination Survey (NHANES; 2007-2020). Kidney stone patients were identified on the basis of their affirmative response to the question \"Have you ever experienced kidney stones?\" (KIQ026). Participants whose T score at the femoral neck was < -2.5 were defined as osteoporosis patients. Multivariable-adjusted logistic regression was used to assess the correlation between the presence of kidney stones and the risk of developing osteoporosis. Second, Mendelian randomization (MR) was applied to further investigate the causal relationship between the presence of kidney stones and the risk of developing osteoporosis. Genetic instruments were obtained from large genome-wide association studies (GWASs) from the UK Biobank and FinnGen Biobank. Inverse-variance weighting (IVW) was the primary analytical method used.</p><p><strong>Results: </strong>After adjustment for demographic and other covariates, a significant association between the presence of kidney stones and the risk of developing osteoporosis was detected (OR 1.778, CI: 1.345-2.351, P < 0.001). The MR results further revealed that genetically speaking, the presence of kidney stones was causally associated with a greater risk of developing osteoporosis (IVW: OR 1.088, CI: 1.015-1.167, P < 0.05).</p><p><strong>Conclusion: </strong>The presence of kidney stones is associated with an increased risk of developing osteoporosis. Further prospective cohort studies are needed to validate our results.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"1615-1623"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platinum-based chemotherapies-induced nephrotoxicity: mechanisms, potential treatments, and management.","authors":"Fatemeh Shahrahmani, Sana Badamchizadeh, Fatemeh Kaihani, Sepideh Alavi-Moghadam, Sara Keshtkari, Mostafa Rezaei-Tavirani, Rasta Arjmand, Bagher Larijani, Babak Arjmand","doi":"10.1007/s11255-024-04303-2","DOIUrl":"10.1007/s11255-024-04303-2","url":null,"abstract":"<p><p>Platinum-based chemotherapies are essential in the treatment of several malignancies. However, such medications can damage the kidneys, frequently leading to both acute and chronic kidney disease. Treatment becomes more difficult for such problems. Physicians may alter chemotherapy regimens and utilize kidney-protecting medications to lessen renal damage. New imaging techniques and biomarkers also aid in the early detection of renal issues. To effectively handle the mentioned situation, oncologists, nephrologists, and pharmacists must collaborate. However, additional study is still required to develop customized therapies, discover strategies to minimize kidney injury and produce new platinum medicines. Hereupon, the present review's authors are being sought to address the causes, prospective treatments, and management of nephrotoxicity caused by platinum-based chemotherapy.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"1563-1583"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between hand grip strength and chronic kidney disease progression: insights from SMP-CKD studies.","authors":"Qiong Huang, Linyi Chen, Wenwei Ouyang, Xi-Na Jie, Li-Zhe Fu, Fang Tang, Jing Wang, Yifan Wu, Xusheng Liu","doi":"10.1007/s11255-025-04457-7","DOIUrl":"https://doi.org/10.1007/s11255-025-04457-7","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to investigate the relationship between handgrip strength (HGS) and the progression of chronic kidney disease (CKD) in non-dialysis patients in China, as part of the Self-Management Program for Patients with CKD Cohort (SMP-CKD).</p><p><strong>Methods: </strong>In the SMP-CKD cohort, we utilized Cox regression and Kaplan-Meier survival analysis to explore the association between HGS and CKD progression. Data were stratified by sex-specific HGS quartiles, sarcopenia status, and HGS thresholds. The HGS thresholds were determined through curve analysis of HGS against composite renal outcomes. Group differences were compared to assess the impact of HGS on CKD outcomes.</p><p><strong>Results: </strong>A total of 441 participants (mean age 57.0 ± 17 years, 56.0% male) with CKD stages 3-5 from the SMP-CKD cohort who underwent grip strength evaluation between April 2019 and June 2024 were included in the analysis. The findings revealed that participants in the highest bilateral HGS quartile had a significantly lower risk of renal endpoints, with a hazard ratio (HR) of 0.102 (95% CI 0.041-0.255) compared to those in the lowest quartile. Patients without sarcopenia had a significantly lower risk of CKD composite outcomes, including increased serum creatinine or acute CKD exacerbations (HR 0.422, 95% CI 0.211-0.844, p < 0.012), as well as severe renal endpoints (HR 0.265, 95% CI 0.101-0.694, p < 0.003). Gender-specific cutoffs identified through log-rank test were 63.7 kg for men and 34.6 kg for women. Participants with bilateral HGS above these thresholds demonstrated better renal outcomes, underscoring the protective effect of higher HGS against CKD progression.</p><p><strong>Conclusion: </strong>The study provides strong evidence that HGS is a crucial factor in reducing the risk of CKD progression. Higher levels of HGS are significantly associated with a lower occurrence of renal endpoint events.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}